These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31756535)

  • 1. Anti-Thymocyte Globulin Prophylaxis Induces a Decrease in Naive Th Cells to Inhibit the Onset of Chronic Graft-versus-Host Disease: Results from the Canadian Bone Marrow Transplant Group (CBMTG) 0801 Study.
    Naeije L; Kariminia A; Abdossamadi S; Azadpour S; Subrt P; Kuzeljevic B; Irvine MA; Walker I; Schultz KR
    Biol Blood Marrow Transplant; 2020 Mar; 26(3):438-444. PubMed ID: 31756535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naive and Stem Cell Memory T Cell Subset Recovery Reveals Opposing Reconstitution Patterns in CD4 and CD8 T Cells in Chronic Graft vs. Host Disease.
    Soares MV; Azevedo RI; Ferreira IA; Bucar S; Ribeiro AC; Vieira A; Pereira PNG; Ribeiro RM; Ligeiro D; Alho AC; Soares AS; Camacho N; Martins C; Lourenço F; Moreno R; Ritz J; Lacerda JF
    Front Immunol; 2019; 10():334. PubMed ID: 30894856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial.
    Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
    Lancet Oncol; 2016 Feb; 17(2):164-173. PubMed ID: 26723083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Age Related Differences in the Biology of Chronic Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation".
    Cuvelier GDE; Li A; Drissler S; Kariminia A; Abdossamadi S; Rozmus J; Chanoine JP; Ng B; Mostafavi S; Brinkman RR; Schultz KR
    Front Immunol; 2020; 11():571884. PubMed ID: 33193355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of low-dose anti-thymocyte globulin on immune reconstitution after allogeneic hematopoietic cell transplantation.
    Ito A; Kitano S; Tajima K; Kim Y; Tanaka T; Inamoto Y; Kim SW; Yamamoto N; Fukuda T; Okamoto S
    Int J Hematol; 2020 Jan; 111(1):120-130. PubMed ID: 31641956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High serum level of antithymocyte globulin immediately before graft infusion is associated with a low likelihood of chronic, but not acute, graft-versus-host disease.
    Chawla S; Dharmani-Khan P; Liu Y; Prokopishyn N; Amlish Munir M; Griffiths C; Khan FM; Stewart DA; Russell JA; Daly A; Storek J
    Biol Blood Marrow Transplant; 2014 Aug; 20(8):1156-62. PubMed ID: 24727330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes with low dose anti-thymocyte globulin in patients undergoing matched unrelated donor allogeneic hematopoietic cell transplantation.
    Mountjoy L; Jain T; Kunze KL; Khera N; Sproat LZ; Jennifer W; McCallen M; Leis JF; Noel P; Slack JL; Palmer J
    Leuk Lymphoma; 2020 Aug; 61(8):1996-2002. PubMed ID: 32281491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.
    Socié G; Schmoor C; Bethge WA; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Finke J;
    Blood; 2011 Jun; 117(23):6375-82. PubMed ID: 21467544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial.
    Chang YJ; Wang Y; Mo XD; Zhang XH; Xu LP; Yan CH; Chen H; Chen YH; Chen Y; Han W; Wang FR; Wang JZ; Liu KY; Huang XJ
    Cancer; 2017 Aug; 123(15):2881-2892. PubMed ID: 28301690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life of patients after allogeneic hematopoietic stem cell transplantation with antihuman thymocyte globulin.
    Yu ZP; Ding JH; Wu F; Liu J; Wang J; Cheng J; Zhao G
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):593-9. PubMed ID: 21846461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis.
    Admiraal R; van Kesteren C; Jol-van der Zijde CM; Lankester AC; Bierings MB; Egberts TC; van Tol MJ; Knibbe CA; Bredius RG; Boelens JJ
    Lancet Haematol; 2015 May; 2(5):e194-203. PubMed ID: 26688094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-thymocyte globulin improves survival free from relapse and graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in patients with Philadelphia-negative acute lymphoblastic leukemia: An analysis by the Acute Leukemia Working Party of the EBMT.
    Czerw T; Labopin M; Giebel S; Socié G; Volin L; Fegueux N; Masszi T; Blaise D; Chaganti S; Cornelissen JJ; Passweg J; Maertens J; Itälä-Remes M; Wu D; Mohty M; Nagler A
    Cancer; 2018 Jun; 124(12):2523-2533. PubMed ID: 29603136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial Role of Low-Dose Antithymocyte Globulin in Unrelated Stem Cell Transplantation for Adult Patients with Acquired Severe Aplastic Anemia: Reduction of Graft-versus-Host Disease and Improvement of Graft-versus-Host Disease-Free, Failure-Free Survival Rate.
    Park SS; Kwak DH; Jeon YW; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Cho SG; Kim DW; Min WS; Lee JW
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1498-1508. PubMed ID: 28554856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation.
    Bosch M; Dhadda M; Hoegh-Petersen M; Liu Y; Hagel LM; Podgorny P; Ugarte-Torres A; Khan FM; Luider J; Auer-Grzesiak I; Mansoor A; Russell JA; Daly A; Stewart DA; Maloney D; Boeckh M; Storek J
    Cytotherapy; 2012 Nov; 14(10):1258-75. PubMed ID: 22985195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does anti-thymocyte globulin have a place in busulfan/fludarabine conditioning for matched related donor hematopoietic stem cell transplantation?
    Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Kim CK; Lee KT; Won JH; Hong DS
    Korean J Intern Med; 2016 Jul; 31(4):750-61. PubMed ID: 27017944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does Lymphocyte Count Impact Dosing of Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplantation?
    Heelan F; Mallick R; Bryant A; Radhwi O; Atkins H; Huebsch L; Bredeson C; Allan D; Kekre N
    Biol Blood Marrow Transplant; 2020 Jul; 26(7):1298-1302. PubMed ID: 32165325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
    Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
    Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Comparison of Non-Myeloablative Conditioning with Anti-Thymocyte Globulin and Fludarabine for Patients with Hematologic Malignancies.
    Li Q; Meng F; Zhou M; Yu B; Mo W; Du Q; Jiang X; Wei Y
    Med Sci Monit; 2015 Aug; 21():2257-65. PubMed ID: 26238068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies.
    Schultz KR; Kariminia A; Ng B; Abdossamadi S; Lauener M; Nemecek ER; Wahlstrom JT; Kitko CL; Lewis VA; Schechter T; Jacobsohn DA; Harris AC; Pulsipher MA; Bittencourt H; Choi SW; Caywood EH; Kasow KA; Bhatia M; Oshrine BR; Flower A; Chaudhury S; Coulter D; Chewning JH; Joyce M; Savasan S; Pawlowska AB; Megason GC; Mitchell D; Cheerva AC; Lawitschka A; Azadpour S; Ostroumov E; Subrt P; Halevy A; Mostafavi S; Cuvelier GDE
    Blood; 2020 Apr; 135(15):1287-1298. PubMed ID: 32047896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial.
    Gooptu M; Kim HT; Chen YB; Rybka W; Artz A; Boyer M; Johnston L; McGuirk J; Shea TC; Jagasia M; Shaughnessy PJ; Reynolds CG; Fields M; Alyea EP; Ho VT; Glavin F; Dipersio JF; Westervelt P; Ritz J; Soiffer RJ
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2216-2223. PubMed ID: 30006305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.